Guidance for Industry: Supplemental Guidance on Testing for Replication Competent Retrovirus in Retroviral Vector Based Gene Therapy Products and During Follow-up of Patients in Clinical Trials Using Retroviral Vectors, CBER, Biologics
via Whats New Vaccines Blood Biologics RSS Feed http://bit.ly/2LKsVJw
No comments:
Post a Comment